Skip to main content

Table 4 Years of potential life lost (YPLL) stratified by selected characteristics among patients with ATTR-CM compared to an age and sex-matched general population (years)

From: Clinical manifestation, economic burden, and mortality in patients with transthyretin cardiac amyloidosis

 

No. of patients

No. of death, n (%)

Age at diagnosis, mean (SD)

Age at death, mean (SD)

YPLL (years), mean (SD)

Total

175

62 (35.4)

75.2 (10.6)

75.9 (10.5)

13.0 (7.7)

Age group (years)

 < 65

48

9 (18.8)

56.8 (3.8)

57.8 (4.3)

27.4 (5.0)

 ≥ 65

127

53 (41.7)

78.3 (7.8)

79.0 (7.7)

10.5 (4.8)

Sex

 Male

110

38 (34.5)

75.1 (10.9)

76.0 (10.7)

12.0 (7.0)

 Female

65

24 (36.9)

75.3 (10.3)

75.9 (10.3)

14.6 (8.6)

CCI

 < 3

87

21 (24.1)

69.9 (11.3)

71.1 (11.2)

16.4 (9.2)

 ≥ 3

88

41 (46.6)

77.9 (9.2)

78.4 (9.2)

11.2 (6.2)

History of diseases

 Cardiac manifestation

  Hypertension

90

33 (36.7)

77.2 (8.3)

77.9 (8.4)

11.5 (5.9)

  Atrial fibrillation

36

13 (36.1)

78.3 (8.6)

79.1 (8.2)

10.6 (4.5)

  Other cardiovascular disease

95

36 (37.9)

75.3 (11.2)

76.1 (11.1)

13.5 (8.4)

 Non-cardiac manifestation

  Musculoskeletal disease

119

52 (43.7)

76.3 (10.4)

77.1 (10.2)

12.3 (7.3)

  Depression, anxiety, insomnia

77

34 (44.2)

75.9 (9.9)

76.6 (9.8)

12.8 (7.4)

  Peripheral neuropathy

59

29 (49.2)

75.7 (8.8)

76.4 (8.5)

12.8 (6.5)

  Diabetes mellitus

57

22 (38.6)

75.7 (9.1)

76.5 (9.3)

12.7 (7.3)

  Malignancy

17

5 (29.4)

83.4 (3.1)

84.4 (2.5)

7.4 (1.8)

  Dementia

9

9 (100.0)

83.6 (7.7)

83.9 (7.6)

7.9 (3.7)

  1. ATTR-CM Transthyretin amyloid cardiomyopathy, CCI Charlson comorbidity index, SD Standard deviation, YPLL Years of potential life lost